Cetuximab and Nimotuzumab in Head and Neck Cancer

Both block EGFR, a growth-signal switch on the surface of head and neck cancer cells, and both are given weekly with radiotherapy. The differences are practical. Cetuximab is a chimeric antibody dosed by body surface area, approved worldwide, and it causes an acne-like rash in most patients. Nimotuzumab is a humanised antibody given as a flat weekly dose, licensed chiefly in India, and severe rash with it is uncommon.

The reason for the rash difference is worth understanding, because it explains almost everything else. Cetuximab binds EGFR tightly wherever it finds it. Normal skin carries EGFR too, which is why the rash is so predictable. Nimotuzumab binds with intermediate affinity and needs to attach at two points at once to hold on, so it attaches efficiently only where the receptor is densely packed — as it is on tumour cells — and largely passes over normal skin.

That is a real pharmacological difference, not marketing. It does not, on its own, make one medicine better than the other. It makes them different medicines to live with.

Not in the way most people mean the word. Both are monoclonal antibodies, so they sit in the wider family of medicines derived from the immune system. Neither is a checkpoint inhibitor. They do not take a brake off your immune system. They block a growth signal on the cancer cell, and any immune involvement is secondary.

This is the confusion that sends most people to a page like this one. These two medicines have been in Indian practice since 2006, years before the checkpoint inhibitors arrived, and they were introduced as targeted therapy. Hospital paperwork, day-care registers and insurance pre-authorisation forms now often file them under immunotherapy, because a monoclonal antibody is an immunological product. So a family is told their relative is on immunotherapy, searches the word, and reads about a completely different class of drug.

The practical consequence is the side effects. Checkpoint inhibitors can inflame the gut, lungs, thyroid, liver or adrenal glands — that is what an immune-related adverse event means. EGFR antibodies do not behave that way. Their signature problem is the skin, and with cetuximab, the blood magnesium level. If you have been reading about colitis and pneumonitis in preparation for one of these two drugs, you have been reading about the wrong medicine.

It matters for the paperwork too. Insurers and government schemes word their cover differently for targeted therapy and for immunotherapy, and these two antibodies sit awkwardly across that line. Ask the insurer which heading the claim is being assessed under before the first dose, and ask for the answer in writing.

For a patient fit enough to receive it, cisplatin with radiotherapy remains the standard treatment for locally advanced head and neck cancer, and neither antibody displaces it. Cetuximab with radiotherapy is the recognised option when cisplatin cannot be given. Nimotuzumab is used mainly in India, added to chemoradiation or given where platinum is not possible.

Most of the argument about these two medicines is really an argument about cisplatin. The question a tumour board is answering is not “which antibody”, it is “can this person tolerate platinum chemotherapy alongside radiation, and if not, what goes in its place”. Kidney function, hearing, age, weight loss and general condition decide that, and the antibody question only opens once the answer is no.

Because it was tested against cisplatin and did not match it. Two randomised trials reported in 2019, RTOG 1016 and De-ESCALaTE HPV, compared cetuximab plus radiotherapy against cisplatin plus radiotherapy in HPV-positive oropharyngeal cancer. Cisplatin remained the stronger arm, and guideline bodies did not adopt cetuximab as a gentler substitute.

This is the single most commonly misunderstood fact about cetuximab, and it is misunderstood in a specific direction. The phrase “targeted therapy” sounds precise and mild next to “chemotherapy”, and cetuximab does avoid some of what cisplatin does to the kidneys and hearing. Families therefore ask whether the antibody can be given instead. Where cisplatin is possible, the honest answer from the trial evidence is that swapping it out is a step down, not a step sideways.

NCCN keeps cetuximab with radiotherapy as an option for people who genuinely cannot receive cisplatin. That is a different statement from saying it is an alternative anyone may choose. If your team is offering cisplatin, being told an antibody exists is not the same as being told it would serve you better — and that is a fair question to put to them directly.

Not the difference most families expect. Nimotuzumab is Indian-made, so it is widely assumed to be the cheap option. On published Indian retail listings its per-vial price is the higher of the two, and cetuximab now has Indian-made brands listed far below the originator. The vial price is also not the course price.

The assumption is understandable. Nimotuzumab was launched in 2006 as India’s first indigenously produced novel monoclonal antibody, and “made here, therefore cheaper” has held true for a great many cancer medicines since. It does not clearly hold for this pair any more, because cetuximab has been in India long enough for Indian manufacturers to enter with their own brands.

Four things make a vial-to-vial comparison unreliable, and they all push in different directions. The dosing basis differs, so cetuximab’s vial count rises with body size while nimotuzumab’s does not. The vial sizes differ, 100 mg against 50 mg, so the headline numbers are not describing the same quantity of medicine. Hospital pharmacies buy at procurement rates rather than the listed maximum retail price. And the number of weeks tracks the radiotherapy course rather than a fixed count of doses.

There is also a larger point that gets lost in the comparison. On a locally advanced head and neck plan, the antibody is rarely the whole bill. Radiotherapy over several weeks, cisplatin where it is used, day-care and nursing charges, weekly blood tests, feeding support during mucositis, and response imaging are all billed separately, and together they usually exceed the drug. Response-assessment PET-CT is generally coordinated at partner imaging centres rather than performed in the treating unit, and is billed on its own.

The only figure that answers the real question is a written, itemised estimate from the treating hospital’s billing desk, covering the antibody, the radiotherapy course, the chemotherapy, day-care charges and imaging as separate lines. Ask for it before the first dose, and ask the insurer or scheme desk in the same week whether each of those lines is covered.

Both are intravenous infusions given in a hospital day-care unit, once a week, running alongside the radiotherapy course. Cetuximab starts with a larger loading dose and a longer first infusion, then settles into shorter weekly doses. Nimotuzumab is a flat dose and a shorter infusion from the start. Both are cold-chain biologicals stored between 2°C and 8°C.

1. Before the first dose. The biopsy confirms squamous cell carcinoma, the radiotherapy plan is finalised, and baseline blood counts, kidney and liver function, electrolytes and magnesium are checked. Where cisplatin is planned, hearing is assessed too. Pregnancy status is checked and contraception discussed with both partners.
2. On infusion day. An antihistamine is usually given first. The vial comes out of cold storage and is infused, commonly timed around that day’s radiation. Staff watch for infusion reactions during the drip and for a period afterwards, which is why the first dose takes the longest.
3. Through the course. Dosing continues weekly for as long as the radiotherapy plan runs. Attendance on radiotherapy days matters more to the plan than the antibody schedule does — missed radiation fractions weaken the whole treatment.
4. Between doses. Weekly bloods track magnesium, electrolytes and counts. Skin and mouth are reviewed each week, because rash from the antibody and soreness from the radiation overlap in the same area and are managed differently.

Dose and schedule are set by your oncologist against the approved label and your treatment plan. Nothing on this page is a dosing instruction.

Yes, and this is the clearest practical difference between them. Cetuximab causes an acne-like rash on the face, scalp and upper body in most patients, and it can be severe. Nimotuzumab rarely does. Cetuximab also lowers blood magnesium often enough to be monitored every week. Neither causes the immune-related organ inflammation seen with checkpoint inhibitors.

Because both are given with radiotherapy, a good deal of what patients experience — mouth ulcers, a raw throat, difficulty swallowing, sore skin over the treated area, taste change and weight loss — comes mainly from the radiation rather than from the antibody. Separating the two is a job for the treating team at the weekly review, not something to work out at home.

The cetuximab rash is not an allergy and is not a reason to stop treatment on your own. It is managed by the oncology team, sometimes with a dose adjustment. What it does need is reporting rather than tolerating in silence, because it is easier to control early.

Symptoms that need urgent assessment rather than home management, on either medicine: breathlessness, wheeze, dizziness or swelling of the face, lips or throat during an infusion or in the hours after it; fever with chills; chest pain; a rash that blisters or peels, or sores involving the mouth or eyes; being unable to swallow or keep fluids down; or severe unexplained weakness. Contact your treating oncology team immediately, or go to the nearest emergency department. Do not wait for the next scheduled dose, and tell any doctor who sees you which antibody you are on.

Six questions turn this comparison into something usable in a consulting room.

1. Am I fit for cisplatin with radiotherapy — and if not, exactly which finding rules it out?
2. Is the antibody being added to chemoradiation, or used in place of chemotherapy?
3. Which molecule and which brand, and is it the originator or an Indian-made version of the same molecule?
4. How many doses does the plan involve, and does that number track the radiotherapy course?
5. Under which heading will the insurer or scheme assess this — targeted therapy or immunotherapy — and can I have that in writing?
6. What is the plan if the rash or the magnesium level becomes a problem partway through?

The fifth question is the one families most often skip and most often regret. These antibodies straddle two claim categories, and a pre-authorisation worded under the wrong heading is a common reason a head and neck claim stalls midway through a radiotherapy course, when stopping is the worst available option.

If it is nimotuzumab specifically that has been prescribed, Nimotuzumab (BIOMAb EGFR) in India: Uses and Cost goes further into its schedule, its Indian evidence base and its published listings than a comparison page can.

To see where these two sit among the antibodies that can actually be obtained in this country, Which Antibody Medicines Are Available in India? maps the whole list, including which molecules are approved here and which are not. Two other antibodies on that list show how differently this class behaves in blood cancers: Brentuximab Vedotin: Uses, Cost and Side Effects is an antibody carrying a chemotherapy payload, and Daratumumab: Uses, Cost and Side Effects in Myeloma is an antibody that works largely by recruiting the immune system — neither of them working the way an EGFR blocker does.

For the full picture across the named medicines, their approval status and their costs, start from Immunotherapy Medicines Explained. For how immunotherapy works as a treatment rather than as a list of molecules — and where targeted antibodies like these two fit into it — the main immunotherapy section is the place to begin.